TrialDiabetes, obesity & metabolism2022

Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.

A secondary analysis of NCT02419612. The report of the trial’s main result is not on the map, and the numbers here are shown and do not vote.

What the trial testedas reported · 382 people · 2022

Not counted

2.1×1.2× to 3.4×

Bigger than 5 in 10 for glycemic control

As reported

OR 2.1, 95% CI 1.23–3.42

the abstract, start to end

… response (HbA1c <53 mmol/mol; odds ratio 2.1, 95% CI 1.23-3.42; P = 0.006).

← favours treatmentfavours comparator →

could be chance

Glycemic control

OR 2.11.23–3.42

MetforminSGLT2 inhibitorsDPP-4 inhibitorsSulfonylureas & glinidesGlycemic control

1 / 3

2022

2023

2024

2025

this paperpooled ittrialcites it